Misato Kaishima, Junichi Ito, Kentaro Takahashi, Kenji Tai, Junro Kuromitsu, Shogyoku Bun, Daisuke Ito
{"title":"日本阿尔茨海默病淀粉样蛋白-β PET成像多基因风险评分模型的建立","authors":"Misato Kaishima, Junichi Ito, Kentaro Takahashi, Kenji Tai, Junro Kuromitsu, Shogyoku Bun, Daisuke Ito","doi":"10.1186/s13195-025-01754-2","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>The use of polygenic risk scores (PRS) for predicting disease risk in Japanese populations, particularly for dementia and related phenotypes, remains markedly unexplored. The aim of this study was to bridge this gap by developing a novel PRS model designed to predict amyloid-β (Aβ) deposition utilizing positron emission tomography (PET) imaging data from a Japanese cohort.</p><p><strong>Methods: </strong>Using the polygenic risk score-continuous shrinkage (PRS-CS) algorithm, we calculated PRS based on significant single nucleotide polymorphisms (SNPs) associated with Alzheimer's disease (AD) in this population. We applied a PRS calculation approach informed by Japanese genome-wide association studies (GWAS) summary statistics into a Japanese dementia cohort from Keio University.</p><p><strong>Results: </strong>Our findings revealed that a p-value threshold of pT < 0.1 optimally enhanced the predictive capability of the Japanese Aβ PET positivity risk model. Moreover, we demonstrated that distinguishing between the counts of APOE2 and APOE4 alleles in our calculations significantly elevated model performance, achieving an area under the curve (AUC) of 0.759. Remarkably, this predictive accuracy remained robust even when the pT was adjusted to be < 1.0 × 10<sup>- 5</sup>, maintaining an AUC of 0.735. This study validated the efficacy of the model in identifying individuals with a increased risk of amyloid pathology.</p><p><strong>Conclusions: </strong>These findings highlight the potential of PRS as a noninvasive tool for early detection and risk stratification of AD, which could lead to enhanced clinical applications and interventions.</p>","PeriodicalId":7516,"journal":{"name":"Alzheimer's Research & Therapy","volume":"17 1","pages":"112"},"PeriodicalIF":7.9000,"publicationDate":"2025-05-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12096521/pdf/","citationCount":"0","resultStr":"{\"title\":\"Development of a Japanese polygenic risk score model for amyloid-β PET imaging in Alzheimer's disease.\",\"authors\":\"Misato Kaishima, Junichi Ito, Kentaro Takahashi, Kenji Tai, Junro Kuromitsu, Shogyoku Bun, Daisuke Ito\",\"doi\":\"10.1186/s13195-025-01754-2\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>The use of polygenic risk scores (PRS) for predicting disease risk in Japanese populations, particularly for dementia and related phenotypes, remains markedly unexplored. The aim of this study was to bridge this gap by developing a novel PRS model designed to predict amyloid-β (Aβ) deposition utilizing positron emission tomography (PET) imaging data from a Japanese cohort.</p><p><strong>Methods: </strong>Using the polygenic risk score-continuous shrinkage (PRS-CS) algorithm, we calculated PRS based on significant single nucleotide polymorphisms (SNPs) associated with Alzheimer's disease (AD) in this population. We applied a PRS calculation approach informed by Japanese genome-wide association studies (GWAS) summary statistics into a Japanese dementia cohort from Keio University.</p><p><strong>Results: </strong>Our findings revealed that a p-value threshold of pT < 0.1 optimally enhanced the predictive capability of the Japanese Aβ PET positivity risk model. Moreover, we demonstrated that distinguishing between the counts of APOE2 and APOE4 alleles in our calculations significantly elevated model performance, achieving an area under the curve (AUC) of 0.759. Remarkably, this predictive accuracy remained robust even when the pT was adjusted to be < 1.0 × 10<sup>- 5</sup>, maintaining an AUC of 0.735. This study validated the efficacy of the model in identifying individuals with a increased risk of amyloid pathology.</p><p><strong>Conclusions: </strong>These findings highlight the potential of PRS as a noninvasive tool for early detection and risk stratification of AD, which could lead to enhanced clinical applications and interventions.</p>\",\"PeriodicalId\":7516,\"journal\":{\"name\":\"Alzheimer's Research & Therapy\",\"volume\":\"17 1\",\"pages\":\"112\"},\"PeriodicalIF\":7.9000,\"publicationDate\":\"2025-05-22\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12096521/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Alzheimer's Research & Therapy\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1186/s13195-025-01754-2\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"CLINICAL NEUROLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Alzheimer's Research & Therapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1186/s13195-025-01754-2","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
引用次数: 0
摘要
背景:使用多基因风险评分(PRS)预测日本人群的疾病风险,特别是痴呆和相关表型的风险,仍未得到充分的探索。本研究的目的是通过开发一种新的PRS模型来弥补这一空白,该模型旨在利用来自日本队列的正电子发射断层扫描(PET)成像数据来预测淀粉样蛋白-β (a β)沉积。方法:采用多基因风险评分-连续收缩(PRS- cs)算法,基于该人群中与阿尔茨海默病(AD)相关的显著单核苷酸多态性(snp)计算PRS。我们将日本全基因组关联研究(GWAS)汇总统计的PRS计算方法应用于来自庆应义塾大学的日本痴呆队列。结果:我们的研究结果显示,p值阈值为pT - 5, AUC维持在0.735。这项研究验证了该模型在识别淀粉样蛋白病理风险增加的个体方面的功效。结论:这些发现突出了PRS作为早期发现和风险分层的无创工具的潜力,这可能会导致临床应用和干预的加强。
Development of a Japanese polygenic risk score model for amyloid-β PET imaging in Alzheimer's disease.
Background: The use of polygenic risk scores (PRS) for predicting disease risk in Japanese populations, particularly for dementia and related phenotypes, remains markedly unexplored. The aim of this study was to bridge this gap by developing a novel PRS model designed to predict amyloid-β (Aβ) deposition utilizing positron emission tomography (PET) imaging data from a Japanese cohort.
Methods: Using the polygenic risk score-continuous shrinkage (PRS-CS) algorithm, we calculated PRS based on significant single nucleotide polymorphisms (SNPs) associated with Alzheimer's disease (AD) in this population. We applied a PRS calculation approach informed by Japanese genome-wide association studies (GWAS) summary statistics into a Japanese dementia cohort from Keio University.
Results: Our findings revealed that a p-value threshold of pT < 0.1 optimally enhanced the predictive capability of the Japanese Aβ PET positivity risk model. Moreover, we demonstrated that distinguishing between the counts of APOE2 and APOE4 alleles in our calculations significantly elevated model performance, achieving an area under the curve (AUC) of 0.759. Remarkably, this predictive accuracy remained robust even when the pT was adjusted to be < 1.0 × 10- 5, maintaining an AUC of 0.735. This study validated the efficacy of the model in identifying individuals with a increased risk of amyloid pathology.
Conclusions: These findings highlight the potential of PRS as a noninvasive tool for early detection and risk stratification of AD, which could lead to enhanced clinical applications and interventions.
期刊介绍:
Alzheimer's Research & Therapy is an international peer-reviewed journal that focuses on translational research into Alzheimer's disease and other neurodegenerative diseases. It publishes open-access basic research, clinical trials, drug discovery and development studies, and epidemiologic studies. The journal also includes reviews, viewpoints, commentaries, debates, and reports. All articles published in Alzheimer's Research & Therapy are included in several reputable databases such as CAS, Current contents, DOAJ, Embase, Journal Citation Reports/Science Edition, MEDLINE, PubMed, PubMed Central, Science Citation Index Expanded (Web of Science) and Scopus.